Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A fresh market piece frames Johnson & Johnson as a steady income prospect, centering on the core question dividend investors ask: can the company keep paying through changing healthcare conditions?
THE APEX TIMES
THE APEX TIMES
A RiverPark Large Growth Fund letter released this week cited regulatory and pricing policy challenges as headwinds for Eli Lilly, highlighting how policy shifts around high-profile diabetes and obesity drugs can quickly affect market sentiment. Recent reporting also points to ongoing FDA review timing changes and prior U.S. pricing actions tied to GLP-1 medicines.
THE APEX TIMES
The U.S. approval expands the use of palbociclib, marketed as Ibrance, positioning it as a first-of-its-kind CDK4/6 inhibitor maintenance therapy after induction treatment in a specific subtype of advanced breast cancer.
THE APEX TIMES
Eli Lilly and Company (LLY) has been among the most searched stocks recently, a sign that retail and other market participants are closely tracking the company despite a crowded landscape of high-expectation healthcare names.
THE APEX TIMES
The company’s charitable arm says the grants will support local organizations working on health care access, food, stable housing and related services in the Greater Hartford region.
THE APEX TIMES
The company will discuss its second-quarter financial performance with analysts and investors on Wednesday, August 5 at 8:00 a.m. ET, with a live webcast and a replay archived for one year.
THE APEX TIMES
A recent investing column argues that Eli Lilly’s track record has offered a rare mix of defensiveness and upside, though it provides limited new company-specific details.
THE APEX TIMES
The move narrows Lilly’s China footprint in oncology while the company’s stock reaction elsewhere has been driven by strong demand for its weight-loss medicines.
THE APEX TIMES
A new comparison of the two healthcare giants points to higher net income margin at UnitedHealth and a broader slowdown in revenue growth for both companies after a long expansion.
